公开(公告)号：US20220133715A1

公开(公告)日：2022-05-05

申请号：US17434278

申请日：2020-02-26

申请人： OREGON HEALTH & SCIENCE UNIVERSITY

发明人： JEFFREY TYNER ,  TAMILLA NECHIPORUK ,  STEPHEN KURTZ ,  SHANNON MCWEENY

IPC分类号： A61K31/496 ,  A61K31/635 ,  A61P35/02 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/506

摘要： The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in need thereof a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor, or a pharmaceutically acceptable salt thereof.